Frontlight ResearchEarly access
TerminatedPhase 2/3
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
Key facts
- Who runs it
- University of Zurich
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2/3
- People taking part
- 24 people enrolled
- Started
- 15 Jun 2022
- Ended
- 4 Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Application of Tralokinumab
- Record updated
- 6 February 2026
- Why it stopped
- treatment group completed but insufficient recruitment control group
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Inclusion criteria (patients):; Moderate to severe AD; EASI < 50; 18-65 years old; Subject is capable of giving informed consent; Signed informed consent
- No diagnosis or history of atopic dermatitis
- 18-65 years old
- Subject is capable of giving informed consent
- Signed informed consent
Who cannot take part
- Use of systemic corticosteroids or systemic immunosuppressive/immunomodulating drugs within four weeks prior to start of the study
- Use of tanning beds or phototherapy within 6 weeks prior to start of the study
- Known or suspected non-compliance, drug or alcohol abuse,
- Previous enrolment into the current study,
- History of cancer except for treated basal cell or spinal cell carcinoma of the skin
- Active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood. A better understanding of the mechanisms underlying the clinical effects of tralokinumab would be of great clinical benefit since it may ultimately help us to identify more precisely candidate patients who may benefit from a therapy with tralokinumab.
The 2 groups in the trial
- Healthy armNo study treatment, for comparison
Healthy controls
- TralokinumabExisting treatment, for comparison
Patients with AD
Treatment: Application of Tralokinumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation (TRALIS)
- Record updated
- 6 February 2026